Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients

• Published in: Journal of rheumatology Vol. 41; no. 12; p. 2395
• Main Authors: Payet, Judith, Goulvestre, Claire, Bialé, Lisa, Avouac, Jérôme, Wipff, Julien, Job-Deslandre, Chantal, Batteux, Frédéric, Dougados, Maxime, Kahan, André, Allanore, Yannick
• Format: Journal Article
• Language: English
• Published: Canada 01.12.2014
• Subjects: Adult; Aged; Antibodies, Anti-Idiotypic - blood; Arthritis, Juvenile - blood; Arthritis, Juvenile - diagnosis; Arthritis, Juvenile - immunology; Arthritis, Psoriatic - blood; Arthritis, Psoriatic - diagnosis; Arthritis, Psoriatic - immunology; Arthritis, Rheumatoid - blood; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - immunology; Biomarkers - blood; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Systemic - blood; Lupus Erythematosus, Systemic - diagnosis; Lupus Erythematosus, Systemic - immunology; Male; Middle Aged; Mixed Connective Tissue Disease - blood; Mixed Connective Tissue Disease - diagnosis; Mixed Connective Tissue Disease - immunology; Peptides, Cyclic - immunology; Retrospective Studies; Rheumatic Diseases - blood; Rheumatic Diseases - diagnosis; Rheumatic Diseases - immunology; Scleroderma, Systemic - blood; Scleroderma, Systemic - diagnosis; Scleroderma, Systemic - immunology; Sensitivity and Specificity; Sjogren's Syndrome - blood; Sjogren's Syndrome - diagnosis; Sjogren's Syndrome - immunology; RHEUMATOID ARTHRITIS; DIAGNOSIS; ANTICYCLIC CITRULLINATED PEPTIDE ANTIBODIES
• DOI: 10.3899/jrheum.131375
• ISSN: 0315-162X

Anticyclic citrullinated peptide antibodies (anti-CCP) are considered specific markers of rheumatoid arthritis (RA) and have been included in the revised classification criteria for RA diagnosis. However, these antibodies have also been detected in patients with other types of chronic inflammatory rheumatism. Our objectives were to identify the prevalence of positive anti-CCP patients in non-RA diseases, to determine the diagnostic value of anti-CCP for the diagnosis of RA, to specify the clinical characteristics of non-RA patients positive for anti-CCP, and to determine the discriminatory value of the levels of anti-CCP in patients among the various diseases. We carried out an observational and descriptive study. All the determinations of anti-CCP requested by the 2 rheumatology departments at Cochin Hospital over a period of 18 months were analyzed. Such determinations were requested for 1162 patients in total. Anti-CCP levels were determined with the Euro Diagnostica ELISA kit, with values ≥ 25 U for this test being considered positive. The diagnosis of rheumatic conditions was the responsibility of the treating physician. Anti-CCP antibodies were detected in 357 (30.7%) of the 1162 patients. The prevalence of anti-CCP was 292/417 (70.0%) in RA, 13/122 (10.6%) in patients with psoriatic arthritis, 13/62 (20.9%) in patients with unclassified rheumatism, 11/33 (33.3%) in patients with primary Sjögren syndrome, 5/30 (16.6%) in patients with systemic lupus erythematosus, 3/28 (10.7%) in patients with mixed connective tissue disorder, 3/36 (8.3%) in patients with systemic sclerosis, 7/44 (15.9%) in patients with juvenile arthritis, and 6/220 (2.7%) in patients with noninflammatory diseases. In the population of patients positive for anti-CCP, mean anti-CCP levels were 869.4 (± 978.4) U/ml, with no significant difference between RA [854.8 (± 959.8) U/ml] and any of the non-RA conditions [922.7 (± 1070.0) U/ml]. Anti-CCP are a hallmark of RA, but may be observed in other inflammatory, systemic, or mechanical diseases. In this large cohort of patients, the presence of second-generation anti-CCP (anti-CCP2) antibodies is useful in diagnosing RA (70% sensitivity, 91.3% specificity), but examining the levels of these antibodies does not appear to offer further discriminatory power among patients who are anti-CCP2-positive.